This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Over the age of 21
Must have an informant who will be able to provide independent evaluation of functioning
English is primary language
All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
If you have had a stroke or tumor that could explain your symptoms
Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
Subjects will be excluded if they have poor vision (20/400)
Single group
F-18 AV 1451
DrugTau binding agent
C-11 PiB
DrugAmyloid binding agent
Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
Rates of change in amyloid-PET burden over time.
Rates of change in tau-PET burden over time.
Click on the lead sponsor to view all of their trials.
Mayo Clinic
Lead sponsor
National Institute on Aging (NIA)
Collaborator
